AUPH Aurinia Pharmaceuticals Inc.
Healthcare$15.19-0.20%ClosedMarket Cap: $1.95B
As of 2026-05-26
Valuation
P/E (TTM)
7.30
PEG
0.00
P/B
3.55
P/S
6.56
EV/EBITDA
12.27
DCF Value
$-48.57
FCF Yield
8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.7%
Operating Margin
41.7%
Net Margin
100.0%
ROE
64.5%
ROA
41.2%
ROIC
19.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $77.7M | 91.6% | $41.4M | $34.4M | $— | — |
| Q4 null | $77.1M | 89.0% | $33.2M | $210.8M | $— | — |
| FY null | $283.1M | 88.5% | $104.9M | $287.2M | $— | — |
| Q3 null | $73.5M | 88.4% | $29.7M | $31.6M | $— | — |
| Q2 null | $70.0M | 89.8% | $20.1M | $21.5M | $— | — |
| Q1 null | $62.5M | 86.3% | $21.8M | $23.3M | $— | — |
| Q4 null | $59.9M | 90.7% | $-1.7M | $1.4M | $— | — |
| FY null | $235.1M | 88.0% | $-4.7M | $5.8M | $— | — |
| Q3 null | $67.8M | 91.1% | $11.7M | $14.3M | $— | — |
| Q2 null | $57.2M | 84.4% | $-1.5M | $722.0K | $— | — |
| Q1 null | $50.3M | 84.6% | $-10.7M | $-10.7M | $— | — |
| Q4 2023 | $45.1M | 88.0% | $-29.7M | $-26.9M | $-0.19 | — |